(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Quarter results tomorrow
(bmo 2024-05-06)
Expected move: +/- 0.00%
0.48% € 41.80
Live Chart Being Loaded With Signals
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments...
Stats | |
---|---|
Dzisiejszy wolumen | 100.00 |
Średni wolumen | 151.00 |
Kapitalizacja rynkowa | 1.42B |
EPS | €0 ( 2024-03-28 ) |
Następna data zysków | ( €0 ) 2024-05-06 |
Last Dividend | €0.0400 ( 2019-05-08 ) |
Next Dividend | €0 ( N/A ) |
P/E | 13.06 |
ATR14 | €0 (0.00%) |
Biotest AG Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Biotest AG Finanse
Annual | 2023 |
Przychody: | €684.60M |
Zysk brutto: | €271.90M (39.72 %) |
EPS: | €3.21 |
FY | 2023 |
Przychody: | €684.60M |
Zysk brutto: | €271.90M (39.72 %) |
EPS: | €3.21 |
FY | 2022 |
Przychody: | €516.10M |
Zysk brutto: | €124.90M (24.20 %) |
EPS: | €-0.800 |
FY | 2021 |
Przychody: | €515.60M |
Zysk brutto: | €80.70M (15.65 %) |
EPS: | €-1.610 |
Financial Reports:
No articles found.
Biotest AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
First Dividend | €0.0667 | 2000-07-17 |
Last Dividend | €0.0400 | 2019-05-08 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | €1.683 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2 | -- |
Div. Sustainability Score | 7.59 | |
Div.Growth Potential Score | 1.201 | |
Div. Directional Score | 4.40 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MTX.DE | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% | |
2HRA.DE | Ex Dividend Junior | 2023-05-24 | Sporadic | 0 | 0.00% | |
XTP.F | Ex Dividend Junior | 2023-05-12 | Sporadic | 0 | 0.00% | |
ETG.DE | Ex Dividend Knight | 2023-07-04 | Annually | 0 | 0.00% | |
PCG6.F | Ex Dividend Junior | 2023-07-28 | Quarterly | 0 | 0.00% | |
AEND.DE | Ex Dividend Junior | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
HAG.DE | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% | |
SDF.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
BOSS.DE | Ex Dividend Knight | 2023-05-10 | Annually | 0 | 0.00% | |
KBX.DE | Ex Dividend Knight | 2023-05-08 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.217 | 1.500 | 5.65 | 8.48 | [0 - 0.5] |
returnOnAssetsTTM | 0.107 | 1.200 | 6.43 | 7.71 | [0 - 0.3] |
returnOnEquityTTM | 0.368 | 1.500 | 7.02 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.963 | 0.800 | 5.18 | 4.15 | [1 - 3] |
quickRatioTTM | 0.845 | 0.800 | 9.74 | 7.79 | [0.8 - 2.5] |
cashRatioTTM | 0.308 | 1.500 | 9.40 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.441 | -1.500 | 2.64 | -3.97 | [0 - 0.6] |
interestCoverageTTM | 4.47 | 1.000 | 9.46 | 9.46 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0404 | 2.00 | -0.0135 | -0.0270 | [0 - 30] |
freeCashFlowPerShareTTM | -0.884 | 2.00 | -0.442 | -0.884 | [0 - 20] |
debtEquityRatioTTM | 1.278 | -1.500 | 4.89 | -7.33 | [0 - 2.5] |
grossProfitMarginTTM | 0.432 | 1.000 | 6.13 | 6.13 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.251 | 1.000 | 6.98 | 6.98 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.00251 | 1.000 | -1.125 | -1.125 | [0.2 - 2] |
assetTurnoverTTM | 0.493 | 0.800 | -0.0455 | -0.0364 | [0.5 - 2] |
Total Score | 7.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.69 | 1.000 | 9.02 | 0 | [1 - 100] |
returnOnEquityTTM | 0.368 | 2.50 | 8.09 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.884 | 2.00 | -0.295 | -0.884 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0404 | 2.00 | -0.0135 | -0.0270 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.116 | 1.500 | -2.56 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00225 | 1.000 | -2.56 | 0 | [0.1 - 0.5] |
Total Score | 1.201 |
Biotest AG
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej